US diagnostics firm Access Genetics has acquired all assets of California-based company Sensible Diagnostics. Access Genetics subsidiary OralDNA will be assuming ownership of Sensible Diagnostics’ assets and will be commercialising a new point-of-care molecular diagnostics system.
"We are proud to add Sensible Diagnostics' state-of-the-art platform to our capabilities, enhancing our ability to provide real-time, actionable results to clinicians and their patients. This acquisition underscores our commitment to innovation in healthcare diagnostics," said George Hoedeman, CEO at OralDNA Labs.
Access Genetics offers cutting-edge DNA testing at its CLIA-certified and CAP-accredited national reference laboratories. OralDNA® Labs is an innovator in salivary diagnostics with a comprehensive menu of infectious and human genetic markers.
With a fast, 4-channel system and convenient microfluidic test cartridges, OralDNA Labs aims to improve the speed and accuracy of chairside diagnostics. Initial development has focused on the oral microbiome with a plan to support dentists in the diagnosis and treatment of periodontal disease and possibly related oral systemic illnesses. The platform and assays under development have not received FDA clearance and are not currently for sale.